Need a report that reflects how COVID-19 has impacted this market and its growth?
The Europe proteomics market was valued at approximately USD 5,356 million in 2020, and it is expected to witness a revenue of USD 10,793 million in 2026, with a CAGR of 12.4% over the forecast period, 2021-2026.
The COVID-19 pandemic has turned the spotlight on proteomic studies, and thus, it is expected to drive the studied market growth during the present crisis. According to the research article published in the Journal of Proteins and Proteomics, 2020, proteomics and metabolomics are the fields with vast potential to face the current COVID-19 challenge. The SARS-CoV genome encodes 28 proteins of which the structure of 16 proteins or their functional domain has been determined to date. Of these 16 proteins, eight them have novel functional domains that indicate the distinctiveness of coronavirus proteins. The proteomics aids in the identification of the novel biomarkers of the SARS-CoV2 virus, and thus, provides effective opportunities for the point-of-care clinical healthcare deliveries in the most cost-effective manner. Additionally, as per the research article published in Immunity, 2020, the host responses to COVID-19 were profiled by performing plasma proteomics of a cohort of COVID-19 patients and developing a machine-learning-based pipeline to identify 11 proteins as biomarkers, and thus, shed light on potential therapeutic targets of COVID-19. Thus, given the aforementioned applications of proteomics, the COVID-19 pandemic has a positive impact on the growth of the studied market.
Proteomics has received great attention over the last decade, particularly in the field of diagnosis, drug research, and development. It has various applications ranging from identification of proteins to purification and separation of the protein to study the nature and properties. It has vast applications in identifying some protein-related disorders or diseases in the organism. Thus, it is evolving into an important tool in the field of life sciences.
Furthermore, increasing demand for personalized medicine in Europe, along with the presence of key market players such as Merck KGaA, is expected to boost regional growth. Also, positive support from the local authorities in Europe and initiatives by research organizations to advance the proteomics technologies such as chemo proteomics and spectrometry are expected to further fuel the market growth. For instance, in August 2020, Bruker Corporation agreed on a strategic collaboration with Utrecht University to work on the study of the 3D structures and interactions of proteins using mass spectrometry. Also, in January 2019, the European Union granted EUR 10 million to a consortium of eighteen European research groups in the field of mass spectrometry-based proteomics research throughout Europe. Thus, the increasing investment by key players and funding to the research organizations for the advancements in the field of proteomics in Europe are expected to drive the proteomics market growth significantly over the forecast period.
Scope of the report
Proteomics is the study of protein structure and function. At the cellular level, proteomics deals with topics, such as which proteins are expressed, when and where they are expressed, what their structures in both active and inactive states are, what roles they play in the life of the cell, and how they interact with other proteins and molecules. The Europe proteomics market is segmented by products and services, application, and geography. By products and services, the market is segmented into instrumentation technology, reagents, and software and services. By application, the market is segmented into clinical diagnostics, drug discovery, and other applications. By geography, the market is segmented into Germany, United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (in USD million) for the above segments.
|By Products and Services|
|Software and Services|
|Germany (By Products and Services and Application)|
|United Kingdom (By Products and Services and Application)|
|France (By Products and Services and Application)|
|Italy (By Products and Services and Application)|
|Spain (By Products and Services and Application)|
|Rest of Europe (By Products and Services and Application)|
Key Market Trends
The Drug Discovery Segment is Expected to Have a Notable Growth Rate over the Forecast Period in Europe
The identification of novel and effective therapeutics in the treatment of disease has been considered one of the most ongoing developments in the study of human genes and proteins. This process of identification and development is based on genome and proteome information for the detection of proteins associated with a disease, which are later used as targets for new drugs by implementing software technologies.
The growing spending on drug discovery and development by the pharma and biopharmaceutical companies, along with research organizations in the region, is the primary factor for the segment growth over the forecast period.
The impact of COVID-19 on the proteomics market aimed at drug discovery is expected to be significant due to the emerging research activities pertaining to the development of novel drugs in the treatment of COVID-19 infection in the region. In August 2020, the European Consortium was launched to accelerate the research, discovery, and development of immediately required drugs for the treatment of SARS-CoV2 viral infection. Hence, this increases the demand for proteomic based studies, which subsequently drives the studied market during the pandemic.
According to the research article published in Proteomics: Clinical Applications, 2019, the advancements in proteomics, such as the development of thermal proteome profiling, enable comprehensive drug target profiling and contribute to a high value in drug discovery. Additionally, the increasing research funding and ongoing projects by research institutes and major players in Europe, especially in the United Kingdom, drive the demand in the studied market. For instance, in December 2020, the UK Biobank collaborated with Biopharma Consortium comprising ten biopharmaceutical companies, on the Pharma Proteomics Project, for a better understanding of disease processes and supporting innovative drug development. Thus, given the increasing research activities in drug discovery in the European region, the proteomics market is expected to witness significant growth over the forecast period.
To understand key trends, Download Sample Report
The European proteomics market is moderately consolidated and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Merck KGaA, Promega Corporation, Thermo Fisher Scientific Inc., and Waters Corporation are the key players, among others. The companies are involved in various strategies such as new product launches and investments in R&D activities to sustain in the highly competitive environment.
In February 2021, University Hospital, Strasbourg, France, began the clinical trial to evaluate the diagnosis of disseminated Lyme borreliosis by targeted proteomics.
In July 2020, SCIEX (Danaher Corporation) launched the next generation mass spectrometer, the SCIEX Triple Quad 7500 LC-MS/MS System – QTRAP Ready.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Personalized Medicine
4.2.2 Increasing R&D Expenditure and Government Funding for Proteomics
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Products and Services
5.1.1 Instrumentation Technology
188.8.131.52 Protein Microarrays
184.108.40.206 X-ray Crystallography
220.127.116.11 Other Instrumentation Technologies
5.1.3 Software and Services
5.2 By Application
5.2.1 Clinical Diagnostics
5.2.2 Drug Discovery
5.2.3 Other Applications
5.3.1 Germany (By Products and Services and Application)
5.3.2 United Kingdom (By Products and Services and Application)
5.3.3 France (By Products and Services and Application)
5.3.4 Italy (By Products and Services and Application)
5.3.5 Spain (By Products and Services and Application)
5.3.6 Rest of Europe (By Products and Services and Application)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Thermo Fisher Scientific Inc.
6.1.4 Danaher Corporation
6.1.5 Waters Corporation
6.1.6 Promega Corporation
6.1.7 Merck KGaA
6.1.8 Bruker Corporation
6.1.9 Luminex Corporation
6.1.10 PerkinElmer Inc.
6.1.12 Horiba Ltd
6.1.13 Creative Proteomics
6.1.14 Becton, Dickinson and Company
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Europe Proteomics Market market is studied from 2018 - 2026.
What is the growth rate of Europe Proteomics Market?
The Europe Proteomics Market is growing at a CAGR of 12.4% over the next 5 years.
What is Europe Proteomics Market size in 2018?
The Europe Proteomics Market is valued at 5356 Million USD in 2018.
What is Europe Proteomics Market size in 2026?
The Europe Proteomics Market is valued at 10793 Million USD in 2026.
Who are the key players in Europe Proteomics Market?
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Promega Corporation
Are the major companies operating in Europe Proteomics Market.